Lixte Biotechnology Holdings, Inc. Common Stock LIXT
$8.04
+11.82%
at last close
Market Cap$125.01 million
P/E Ratio—
Div Yield—
Volume782.2K
52-Week Range
$0.64$8.25
Key Stats
- Today's Range
- $7.00 – $8.25
- 50-Day Range
- $3.23 – $8.25
- 52-Week Range
- $0.64 – $8.25
- Volume
- 782K shs
- Average Volume
- 340K shs
- Market Cap
- $125.01 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About Lixte Biotechnology Holdings, Inc. Common Stock
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.